Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 13 entries
Sorted by: Best Match Show Resources per page
Thiopurines and the natural course of Crohn's disease: did we finally find the right therapeutic target?.

The American journal of gastroenterology

Rieder F, Reinisch W.
PMID: 24989094
Am J Gastroenterol. 2014 Jul;109(7):1037-40. doi: 10.1038/ajg.2014.162.

The disease course of Crohn's disease (CD) can be highly heterogeneous, leading to stricturing or perforating complications and surgery in the majority of patients. Evidence is accumulating about the lack of efficacy of azathioprine (AZA) started early in the...

Cite
Rieder F, Reinisch W. Thiopurines and the natural course of Crohn's disease: did we finally find the right therapeutic target?. Am J Gastroenterol. 2014;109(7):1037-40doi: 10.1038/ajg.2014.162.
Rieder, F., & Reinisch, W. (2014). Thiopurines and the natural course of Crohn's disease: did we finally find the right therapeutic target?. The American journal of gastroenterology, 109(7), 1037-40. https://doi.org/10.1038/ajg.2014.162
Rieder, Florian, and Reinisch, Walter. "Thiopurines and the natural course of Crohn's disease: did we finally find the right therapeutic target?." The American journal of gastroenterology vol. 109,7 (2014): 1037-40. doi: https://doi.org/10.1038/ajg.2014.162
Rieder F, Reinisch W. Thiopurines and the natural course of Crohn's disease: did we finally find the right therapeutic target?. Am J Gastroenterol. 2014 Jul;109(7):1037-40. doi: 10.1038/ajg.2014.162. PMID: 24989094.
Copy Download .nbib Format: NLM
Response to Magro et al.

The American journal of gastroenterology

Irwin J, Radford-Smith G.
PMID: 26052771
Am J Gastroenterol. 2015 Jun;110(6):931-2. doi: 10.1038/ajg.2015.131.

No abstract available.

Cite
Irwin J, Radford-Smith G. Response to Magro et al. Am J Gastroenterol. 2015;110(6):931-2doi: 10.1038/ajg.2015.131.
Irwin, J., & Radford-Smith, G. (2015). Response to Magro et al. The American journal of gastroenterology, 110(6), 931-2. https://doi.org/10.1038/ajg.2015.131
Irwin, James, and Radford-Smith, Graham. "Response to Magro et al." The American journal of gastroenterology vol. 110,6 (2015): 931-2. doi: https://doi.org/10.1038/ajg.2015.131
Irwin J, Radford-Smith G. Response to Magro et al. Am J Gastroenterol. 2015 Jun;110(6):931-2. doi: 10.1038/ajg.2015.131. PMID: 26052771.
Copy Download .nbib Format: NLM
Evolving medical therapies for Crohn's disease.

Current gastroenterology reports

Mahadevan U, Sandborn WJ.
PMID: 11696284
Curr Gastroenterol Rep. 2001 Dec;3(6):471-6. doi: 10.1007/s11894-001-0067-7.

Medical therapy for Crohn's disease has changed dramatically over the past few years. Physicians have become increasingly willing to use traditional immunosuppressive agents such as azathioprine/6-mercaptopurine (6-MP) and methotrexate as well as new biologic therapies such as infliximab. Azathioprine,...

Cite
Mahadevan U, Sandborn WJ. Evolving medical therapies for Crohn's disease. Curr Gastroenterol Rep. 2001;3(6):471-6doi: 10.1007/s11894-001-0067-7.
Mahadevan, U., & Sandborn, W. J. (2001). Evolving medical therapies for Crohn's disease. Current gastroenterology reports, 3(6), 471-6. https://doi.org/10.1007/s11894-001-0067-7
Mahadevan, U, and Sandborn, W J. "Evolving medical therapies for Crohn's disease." Current gastroenterology reports vol. 3,6 (2001): 471-6. doi: https://doi.org/10.1007/s11894-001-0067-7
Mahadevan U, Sandborn WJ. Evolving medical therapies for Crohn's disease. Curr Gastroenterol Rep. 2001 Dec;3(6):471-6. doi: 10.1007/s11894-001-0067-7. PMID: 11696284.
Copy Download .nbib Format: NLM
[Inflammatory bowel disease: diagnosis and treatment in general practice].

Revue medicale suisse

Frenzer A.
PMID: 21387735
Rev Med Suisse. 2011 Jan 26;7(279):250-1.

No abstract available.

Cite
Frenzer A. Chronisch entzündliche Darmerkrankungen: Diagnostik und Behandlung in der Hausarztpraxis. [Inflammatory bowel disease: diagnosis and treatment in general practice]. Rev Med Suisse. 2011;7(279):250-1
Frenzer, A. (2011). Chronisch entzündliche Darmerkrankungen: Diagnostik und Behandlung in der Hausarztpraxis. [Inflammatory bowel disease: diagnosis and treatment in general practice]. Revue medicale suisse, 7(279), 250-1.
Frenzer, A. "Chronisch entzündliche Darmerkrankungen: Diagnostik und Behandlung in der Hausarztpraxis." [Inflammatory bowel disease: diagnosis and treatment in general practice]. Revue medicale suisse vol. 7,279 (2011): 250-1.
Frenzer A. Chronisch entzündliche Darmerkrankungen: Diagnostik und Behandlung in der Hausarztpraxis. [Inflammatory bowel disease: diagnosis and treatment in general practice]. Rev Med Suisse. 2011 Jan 26;7(279):250-1. German. PMID: 21387735.
Copy Download .nbib Format: NLM
IM-UNITI at Three Years: Stellar Stelara® or Stardust? The Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.

Journal of Crohn's & colitis

Travis S.
PMID: 31605526
J Crohns Colitis. 2020 Jan 01;14(1):1-3. doi: 10.1093/ecco-jcc/jjz133.

No abstract available.

Cite
Travis S. IM-UNITI at Three Years: Stellar Stelara® or Stardust? The Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. J Crohns Colitis. 2020;14(1):1-3doi: 10.1093/ecco-jcc/jjz133.
Travis, S. (2020). IM-UNITI at Three Years: Stellar Stelara® or Stardust? The Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. Journal of Crohn's & colitis, 14(1), 1-3. https://doi.org/10.1093/ecco-jcc/jjz133
Travis, Simon. "IM-UNITI at Three Years: Stellar Stelara® or Stardust? The Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease." Journal of Crohn's & colitis vol. 14,1 (2020): 1-3. doi: https://doi.org/10.1093/ecco-jcc/jjz133
Travis S. IM-UNITI at Three Years: Stellar Stelara® or Stardust? The Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. J Crohns Colitis. 2020 Jan 01;14(1):1-3. doi: 10.1093/ecco-jcc/jjz133. PMID: 31605526.
Copy Download .nbib Format: NLM
Management of Crohn Disease-Reply.

JAMA

Cushing K, Higgins PDR.
PMID: 33944877
JAMA. 2021 May 04;325(17):1794-1795. doi: 10.1001/jama.2021.2921.

No abstract available.

Cite
Cushing K, Higgins PDR. Management of Crohn Disease-Reply. JAMA. 2021;325(17):1794-1795doi: 10.1001/jama.2021.2921.
Cushing, K., & Higgins, P. D. R. (2021). Management of Crohn Disease-Reply. JAMA, 325(17), 1794-1795. https://doi.org/10.1001/jama.2021.2921
Cushing, Kelly, and Higgins, Peter D R. "Management of Crohn Disease-Reply." JAMA vol. 325,17 (2021): 1794-1795. doi: https://doi.org/10.1001/jama.2021.2921
Cushing K, Higgins PDR. Management of Crohn Disease-Reply. JAMA. 2021 May 04;325(17):1794-1795. doi: 10.1001/jama.2021.2921. PMID: 33944877.
Copy Download .nbib Format: NLM
The importance of accounting for immortal time bias in pharmacoepidemiologic analyses.

The American journal of gastroenterology

Targownik L.
PMID: 25646915
Am J Gastroenterol. 2015 Feb;110(2):349. doi: 10.1038/ajg.2014.372.

No abstract available.

Cite
Targownik L. The importance of accounting for immortal time bias in pharmacoepidemiologic analyses. Am J Gastroenterol. 2015;110(2):349doi: 10.1038/ajg.2014.372.
Targownik, L. (2015). The importance of accounting for immortal time bias in pharmacoepidemiologic analyses. The American journal of gastroenterology, 110(2), 349. https://doi.org/10.1038/ajg.2014.372
Targownik, Laura. "The importance of accounting for immortal time bias in pharmacoepidemiologic analyses." The American journal of gastroenterology vol. 110,2 (2015): 349. doi: https://doi.org/10.1038/ajg.2014.372
Targownik L. The importance of accounting for immortal time bias in pharmacoepidemiologic analyses. Am J Gastroenterol. 2015 Feb;110(2):349. doi: 10.1038/ajg.2014.372. PMID: 25646915.
Copy Download .nbib Format: NLM
[Diagnosis and treatment of chronic inflammatory intestinal diseases. 2. Crohn disease].

Kinderarztliche Praxis

Beyreiss K, Bannert N, Cario WR, Fiehring C, Grävinghoff J, Jung G, Schmutzler S, Scholz H, Tambor U.
PMID: 6656097
Kinderarztl Prax. 1983 Oct;51(10):480-6.

No abstract available.

Cite
Beyreiss K, Bannert N, Cario WR, et al. Diagnose und Therapie chronisch entzündlicher Darmerkrankungen. Teil 2: Morbus CROHN. [Diagnosis and treatment of chronic inflammatory intestinal diseases. 2. Crohn disease]. Kinderarztl Prax. 1983;51(10):480-6
Beyreiss, K., Bannert, N., Cario, W. R., Fiehring, C., Grävinghoff, J., Jung, G., Schmutzler, S., Scholz, H., & Tambor, U. (1983). Diagnose und Therapie chronisch entzündlicher Darmerkrankungen. Teil 2: Morbus CROHN. [Diagnosis and treatment of chronic inflammatory intestinal diseases. 2. Crohn disease]. Kinderarztliche Praxis, 51(10), 480-6.
Beyreiss, K, et al. "Diagnose und Therapie chronisch entzündlicher Darmerkrankungen. Teil 2: Morbus CROHN." [Diagnosis and treatment of chronic inflammatory intestinal diseases. 2. Crohn disease]. Kinderarztliche Praxis vol. 51,10 (1983): 480-6.
Beyreiss K, Bannert N, Cario WR, Fiehring C, Grävinghoff J, Jung G, Schmutzler S, Scholz H, Tambor U. Diagnose und Therapie chronisch entzündlicher Darmerkrankungen. Teil 2: Morbus CROHN. [Diagnosis and treatment of chronic inflammatory intestinal diseases. 2. Crohn disease]. Kinderarztl Prax. 1983 Oct;51(10):480-6. German. PMID: 6656097.
Copy Download .nbib Format: NLM
[Treatment of Crohn's disease].

La Revue du praticien

Girodet J, Rougier P, Mignon M, Bonfils S.
PMID: 1006109
Rev Prat. 1976 Dec 21;26(59):4257-63.

No abstract available.

Cite
Girodet J, Rougier P, Mignon M, et al. Traitement actuel de la maladie de Crohn [Treatment of Crohn's disease]. Rev Prat. 1976;26(59):4257-63
Girodet, J., Rougier, P., Mignon, M., & Bonfils, S. (1976). Traitement actuel de la maladie de Crohn [Treatment of Crohn's disease]. La Revue du praticien, 26(59), 4257-63.
Girodet, J, et al. "Traitement actuel de la maladie de Crohn" [Treatment of Crohn's disease]. La Revue du praticien vol. 26,59 (1976): 4257-63.
Girodet J, Rougier P, Mignon M, Bonfils S. Traitement actuel de la maladie de Crohn [Treatment of Crohn's disease]. Rev Prat. 1976 Dec 21;26(59):4257-63. French. PMID: 1006109.
Copy Download .nbib Format: NLM
What is the role of histopathology in the evaluation of disease activity in Crohn's disease?.

Best practice & research. Clinical gastroenterology

Pai RK, Jairath V.
PMID: 31327406
Best Pract Res Clin Gastroenterol. 2019 Feb - Apr;38:101601. doi: 10.1016/j.bpg.2019.02.003. Epub 2019 Feb 15.

Assessment of disease activity is essential for developing and determining appropriate therapy in patients with Crohn's disease. Currently, clinical and endoscopic treatment targets have been proposed, whereas histologic assessment of disease activity is not recommended in expert guidelines. Histologic...

Cite
Pai RK, Jairath V. What is the role of histopathology in the evaluation of disease activity in Crohn's disease?. Best Pract Res Clin Gastroenterol. 2019;38:101601doi: 10.1016/j.bpg.2019.02.003.
Pai, R. K., & Jairath, V. (2019). What is the role of histopathology in the evaluation of disease activity in Crohn's disease?. Best practice & research. Clinical gastroenterology, 38101601. https://doi.org/10.1016/j.bpg.2019.02.003
Pai, Rish K, and Jairath, Vipul. "What is the role of histopathology in the evaluation of disease activity in Crohn's disease?." Best practice & research. Clinical gastroenterology vol. 38 (2019): 101601. doi: https://doi.org/10.1016/j.bpg.2019.02.003
Pai RK, Jairath V. What is the role of histopathology in the evaluation of disease activity in Crohn's disease?. Best Pract Res Clin Gastroenterol. 2019 Feb - Apr;38:101601. doi: 10.1016/j.bpg.2019.02.003. Epub 2019 Feb 15. PMID: 31327406.
Copy Download .nbib Format: NLM
Management of Crohn Disease.

JAMA

Bayoumy AB, de Boer NKH, Mulder CJJ.
PMID: 33944879
JAMA. 2021 May 04;325(17):1793-1794. doi: 10.1001/jama.2021.2918.

No abstract available.

Cite
Bayoumy AB, de Boer NKH, Mulder CJJ. Management of Crohn Disease. JAMA. 2021;325(17):1793-1794doi: 10.1001/jama.2021.2918.
Bayoumy, A. B., de Boer, N. K. H., & Mulder, C. J. J. (2021). Management of Crohn Disease. JAMA, 325(17), 1793-1794. https://doi.org/10.1001/jama.2021.2918
Bayoumy, Ahmed B, et al. "Management of Crohn Disease." JAMA vol. 325,17 (2021): 1793-1794. doi: https://doi.org/10.1001/jama.2021.2918
Bayoumy AB, de Boer NKH, Mulder CJJ. Management of Crohn Disease. JAMA. 2021 May 04;325(17):1793-1794. doi: 10.1001/jama.2021.2918. PMID: 33944879.
Copy Download .nbib Format: NLM
Response to Targownik.

The American journal of gastroenterology

Magro F, Rodrigues-Pinto E, Coelho R, Andrade P, Santos-Antunes J, Lopes S, Camila-Dias C, Macedo G.
PMID: 25646916
Am J Gastroenterol. 2015 Feb;110(2):349-51. doi: 10.1038/ajg.2014.376.

No abstract available.

Cite
Magro F, Rodrigues-Pinto E, Coelho R, et al. Response to Targownik. Am J Gastroenterol. 2015;110(2):349-51doi: 10.1038/ajg.2014.376.
Magro, F., Rodrigues-Pinto, E., Coelho, R., Andrade, P., Santos-Antunes, J., Lopes, S., Camila-Dias, C., & Macedo, G. (2015). Response to Targownik. The American journal of gastroenterology, 110(2), 349-51. https://doi.org/10.1038/ajg.2014.376
Magro, Fernando, et al. "Response to Targownik." The American journal of gastroenterology vol. 110,2 (2015): 349-51. doi: https://doi.org/10.1038/ajg.2014.376
Magro F, Rodrigues-Pinto E, Coelho R, Andrade P, Santos-Antunes J, Lopes S, Camila-Dias C, Macedo G. Response to Targownik. Am J Gastroenterol. 2015 Feb;110(2):349-51. doi: 10.1038/ajg.2014.376. PMID: 25646916.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 13 entries